



Contributors

A. Abas, National Pharmaceutical Control Bureau, Ministry of Health Malaysia, Selangor, Malaysia.

T. Arato, Office of Biologics I, Pharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan.

P.V. C. Babu, Biotherapeutics, Bharat Biotech International Limited, Andhra Pradesh, India.

D. Barbano, National Health Surveillance Agency (ANVISA), Brasília, Brazil.

A. Berghout, Sandoz Biopharmaceuticals, Holzkirchen, Germany.

O. L. J. Casanueva, Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED), Habana, Cuba.

L. G. Castanheira, Efficacy and Safety Evaluation Office, National Health Surveillance Agency (ANVISA), Brasília, Brazil.

R. B. P. Cristiá, Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED), Habana, Cuba.

M. P. Fletcher, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Geneva, Switzerland.

E. Griffiths, Biologics and Genetic Therapies, Biologics and Genetic Therapies Directorate, Health Canada, Ottawa, Canada.

N. Hadavand, Pharmaceutical and Narcotic Affairs Department, Food and Drugs Organization, Ministry of Health and Medical Education, Tehran, Iran.

R. D. Haddadin, Registration Department, Drug Directorate, Jordan Food and Drug Administration, Amman, Jordan.

H. Heim, Federal Institute for Drugs and Medical Devices, Bonn, Germany.

S. D. O. Hernández, Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED), Habana, Cuba.

H. Kang, Quality, Safety, and Standard, Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

A. V. Klein, Biologics and Genetic Therapies Directorate, Health Products and Food Branch, Health Canada, Ottawa, Canada.

I. Knezevic, Quality, Safety, and Standard, Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

C. Liang, National Institutes for Food and Drug Control (NIFDC), Beijing, China.

H. Malhotra, Division of Medical Oncology, SMS Medical College Hospital, Jaipur, India.

R. O. P. Massipe, Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED), Habana, Cuba.

R. B. D. Morales, Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED), Habana, Cuba.

L. M. Muñoz, Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED), Habana, Cuba.

C. Njue, Centre for Vaccine Evaluation Biologics and Genetic Therapies Directorate Health Products and Food Branch, Health Canada, Ottawa, Canada.

Y. H. Núñez, Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED), Habana, Cuba.

Y. Park, Advanced Therapy Products Division, Biopharmaceuticals and Herbal Medicine Bureau, Korea Food & Drug Administration, Chungcheongbuk-do, Republic of Korea.

J. Poh, Health Products Regulation Group, Health Sciences Authority, Singapore.

M. L. Pombo, Pan American Health Organization, Washington DC, USA.

N. Rech, National Health Surveillance Agency (ANVISA), Brasília, Brazil.

V. P. Rodríguez, Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED), Habana, Cuba.

M. Schiestl, International Generic Pharmaceutical Alliance (IGPA); Sandoz GmbH, Kundl, Austria.

Y. Sohn, Biopharmaceuticals and Herbal Medicine Bureau, Korea Food & Drug Administration, Chungcheongbuk-do, Republic of Korea.

S. Suh, Advanced Therapy Products Division, Biopharmaceuticals and Herbal Medicine Bureau, Korea Food & Drug Administration, Chungcheongbuk-do, Republic of Korea.

K. Tam, Health Products Regulation Group, Health Sciences Authority, Singapore.

P. Thanaphollert, Bureau of Drug Control, Thai Food and Drug Administration, Ministry of Public Health, Thailand.

R. Thorpe, Biotherapeutics Group, National Institute for Biological Standards and Control (NIBSC), Potters Bar, UK.

K. Tungsanga, Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

M. Valadkhani, Pharmaceutical and Narcotic Affairs Department, Food and Drugs Organization, Ministry of Health and Medical Education, Tehran, Iran.

M. Wadhwa, Biotherapeutics Group, National Institute for Biological Standards and Control (NIBSC), Potters Bar, UK.

J. Wang, National Institutes for Food and Drug Control (NIFDC), Beijing, China.

T. Yamaguchi, Office of Biologics I, Pharmaceuticals and Medical Devices Agency (PMDA), Tokyo, Japan.

A. Zarbakhsh, Pharmaceutical and Narcotic Affairs Department, Food and Drugs Organization, Ministry of Health and Medical Education, Tehran, Iran.